The DOI matches its Crossref record; 214 of the 214 references it cites were found in a registry or an index.
Systematic review: cardiovascular safety profile of 5‐ HT 4 agonists developed for gastrointestinal disorders
Open accessAbstract
BACKGROUND: The nonselective 5-HT(4) receptor agonists, cisapride and tegaserod have been associated with cardiovascular adverse events (AEs). AIM: To perform a systematic review of the safety profile, particularly cardiovascular, of 5-HT(4) agonists developed for gastrointestinal disorders, and a nonsystematic summary of their pharmacology and clinical efficacy. METHODS: Articles reporting data on cisapride, clebopride, prucalopride, mosapride, renzapride, tegaserod, TD-5108 (velusetrag) and ATI-7505 (naronapride) were identified through a systematic search of the Cochrane Library, Medline, Embase and Toxfile. Abstracts from UEGW 2006-2008 and DDW 2008-2010 were searched for these drug names, and pharmaceutical companies approached to provide unpublished data. RESULTS: Retrieved articles on pharmacokinetics, human pharmacodynamics and clinical data with these 5-HT(4) agonists, are reviewed and summarised nonsystematically. Articles relating to cardiac safety and tolerability of these agents, including any relevant case reports, are reported systematically. Two nonselective 5-HT(4) agonists had reports of cardiovascular AEs: cisapride (QT prolongation) and tegaserod (ischaemia). Interactions with, respectively, the hERG cardiac potassium channel and 5-HT(1) receptor subtypes have been suggested to account for these effects. No cardiovascular safety concerns were reported for the newer, selective 5-HT(4) agonists prucalopride, velusetrag, naronapride, or for nonselective 5-HT(4) agonists with no hERG or 5-HT(1) affinity (renzapride, clebopride, mosapride). CONCLUSIONS: 5-HT(4) agonists for GI disorders differ in chemical structure and selectivity for 5-HT(4) receptors. Selectivity for 5-HT(4) over non-5-HT(4) receptors may influence the agent's safety and overall risk-benefit profile. Based on available evidence, highly selective 5-HT(4) agonists may offer improved safety to treat patients with impaired GI motility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“nonselective 5-HT4 agonists have been linked to a greater frequency of cardiovascular adverse events in clinical trials”
From Serotonin as a link between the gut-brain-microbiome axis in autism spectrum disorders (2018) · cites this paper as [89]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Pharmacological interventions for non-ulcer dyspepsia
Moayyedi, P., Soo, S., Deeks, J. J., DELANEY, B., Innes, M., & Forman, D. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001960 · Cited by 114
RetractedPharmacological interventions for non-ulcer dyspepsia
Moayyedi, P., Shelly, S., Deeks, J. J., Delaney, B., Innes, M., & Forman, D. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001960.pub3 · Cited by 99
RetractedPharmacological interventions for non-ulcer dyspepsia
Moayyedi, P., Soo, S., Deeks, J. J., Delaney, B. C., Innes, M. A., & Forman, D. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001960.pub4 · Cited by 36
RetractedPharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission
Alex, K. D., & Pehek, E. A. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.08.004 · Cited by 658
A placebo-controlled trial of prucalopride for severe chronic constipation
Camilleri, M., Kerstens, R., Rykx, A., & Vandeplassche, L. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800670 · Cited by 576
Self-citationGrider, J. R., Foxx–Orenstein, A. E., & Jin, J. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70203-3 · Cited by 349
Tack, J., van Outryve, M., Beyens, G., Kerstens, R., & Vandeplassche, L. (2009) · Gut · doi:10.1136/gut.2008.162404 · Cited by 347
Self-citationQUIGLEY, E. M. M., VANDEPLASSCHE, L., KERSTENS, R., & AUSMA, J. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03884.x · Cited by 344
Self-citationReview article: metoclopramide and tardive dyskinesia
RAO, A. S., & CAMILLERI, M. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04189.x · Cited by 316
Self-citationBouras, E. P., Camilleri, M., Burton, D., Thomforde, G., Mckinzie, S., & Zinsmeister, A. (2001) · Gastroenterology · doi:10.1053/gast.2001.21166 · Cited by 306
Self-citationTonini, M., Cipollina, L., Poluzzi, E., Crema, F., Corazza, G., & de Ponti, F. (2004) · Alimentary Pharmacology and Therapeutics · doi:10.1111/j.1365-2036.2004.01867.x · Cited by 297
Dumuis, A., Sebben, M., & Bockaert, J. (1989) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00167041 · Cited by 291
Nobili, V., Parkes, J., Bottazzo, G., Marcellini, M., Cross, R., Newman, D., Vizzutti, F., Pinzani, M., & Rosenberg, W. M. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.013 · Cited by 264
Contraindicated Use of Cisapride
Smalley, W. E., Shatin, D., Wysowski, D. K., Gurwitz, J. H., Andrade, S. E., Goodman, M. J., Chan, K. A., Platt, R. G., Schech, S. D., & Ray, W. A. (2000) · JAMA · doi:10.1001/jama.284.23.3036 · Cited by 253
5‐HT 4 receptor agonists: similar but not the same
Maeyer, J. H. D., Lefebvre, R. A., & Schuurkes, J. A. J. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2007.01059.x · Cited by 249
Self-citationThe epidemiology of ischaemic colitis
Higgins, P., Davis, K. J., & Laine, L. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.01903.x · Cited by 235
Blockage of the HERG human cardiac K+channel by the gastrointestinal prokinetic agent cisapride
Mohammad, S., Zhou, Z., Gong, Q., & January, C. T. (1997) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1997.273.5.h2534 · Cited by 227
Bouras, E. P., Camilleri, M., Burton, D., & Mckinzie, S. (1999) · Gut · doi:10.1136/gut.44.5.682 · Cited by 225
Self-citationMcCallum, R. W., Prakash, C., Campoli-Richards, D. M., & Goa, K. L. (1988) · Drugs · doi:10.2165/00003495-198836060-00002 · Cited by 216
5-Hydroxytryptamine4 receptors mediate relaxation of the rat oesophageal tunica muscularis mucosae
Baxter, G. S., Craig, D. A., & Clarke, D. E. (1991) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00169544 · Cited by 203
Claeysen, S., Sebben, M., Bécamel, C., Bockaert, J., & Dumuis, A. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23188-6 · Cited by 197
Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction.
Camilleri, M., Malagelada, J., Abell, T., Brown, M. L., Hench, V. S., & Zinsmeister, A. (1989) · Gastroenterology · doi:10.1016/s0016-5085(89)80068-x · Cited by 188
Self-citationEffect of cisapride on gastric and esophageal emptying in insulin-dependent diabetes mellitus.
Horowitz, M., Maddox, A., Harding, P., Maddern, G., Chatterton, B. E., Wishart, J., & Shearman, D. (1987) · Gastroenterology · doi:10.1016/0016-5085(87)90622-6 · Cited by 187
Corinaldesi, R., Stanghellini, V., Raiti, C., Rea, E., Salgemini, R., & Barbara, L. (1987) · Gut · doi:10.1136/gut.28.3.300 · Cited by 182
Self-citationBlondel, O., Gastineau, M., Dahmoune, Y., Langlois, M., & Fischmeister, R. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70062252.x · Cited by 159
Carlsson, L. G., Amos, G. J., Andersson, B., et al. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36775-8 · Cited by 159
Drolet, B., Khalifa, M., Daleau, P., Hamelin, B. A., & Turgeon, J. (1998) · Circulation · doi:10.1161/01.cir.97.2.204 · Cited by 157
The influence of cisapride on gastric tone and the perception of gastric distension
Tack, J. F., Broeckaert, Coulie, & Janssens (1998) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1998.00366.x · Cited by 153
Self-citationJian, R., Ducrot, F., Piedeloup, C., Mary, J. Y., Najean, Y., & Bernier, J. J. (1985) · Gut · doi:10.1136/gut.26.4.352 · Cited by 151
The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound
Briejer, M. R., Bosmans, J.-P., Daele, P. V., Jurzak, M., Heylen, L. I., Leysen, J. E., Prins, N. H., & Schuurkes, J. A. J. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01087-1 · Cited by 149
Self-citationGastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility.
Briejer, M. R., Akkermans, L. M. A., & Schuurkes, J. A. J. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06935-2 · Cited by 146
Self-citationPan, H., & Galligan, J. J. (1994) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1994.266.2.g230 · Cited by 143
Self-citationStructure of the Human Serotonin 5‐HT4 Receptor Gene and Cloning of a Novel 5‐HT4 Splice Variant
Bender, E., Pindon, A., Oers, I. V., Zhang, Y., Gommeren, W., Verhasselt, P., Jurzak, M., Leysen, J. E., & Luyten, W. H. M. L. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.740478.x · Cited by 141
Impaired transit of chyme in chronic intestinal pseudoobstruction
Camilleri, M., Brown, M. L., & Malagelada, J. (1986) · Gastroenterology · doi:10.1016/0016-5085(86)90631-1 · Cited by 139
Self-citationPrucalopride, a systemic enterokinetic, for the treatment of constipation
Emmanuel, A. V., Roy, A. J., Nicholls, T., & Kamm, M. A. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01272.x · Cited by 133
Expression and function of 5-HT 4 receptors in the mouse enteric nervous system
Liu, M., Geddis, M. S., Wen, Y., Setlik, W., & Gershon, M. D. (2005) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00245.2005 · Cited by 132
Potet, F., Bouyssou, T., Escande, D., & Baró, I. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29223-5 · Cited by 128
Eglen, R. M., Swank, S. R., Walsh, L. K. M., et al. (1990) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1990.tb14113.x · Cited by 128
Coffin, B., Farmachidi, J.-P., Rueegg, P. C., Bastie, A., & Bouhassira, D. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01449.x · Cited by 125
Tegaserod for the treatment of irritable bowel syndrome and chronic constipation
Evans, B. W., Clark, W. K., Moore, D., & Whorwell, P. J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003960.pub3 · Cited by 125
Manini, M. L., Camilleri, M., Goldberg, M., Sweetser, S. R., McKinzie, S., Burton, D. B., Wong, S., Kitt, M. M., Li, Y., & Zinsmeister, A. R. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01378.x · Cited by 123
Self-citationThe 5‐HT4 receptor agonist, tegaserod, is a potent 5‐HT2B receptor antagonist in vitro and in vivo
Beattie, D. T., Smith, J. A. M., Marquess, D. G., et al. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705929 · Cited by 121
Diego, J. M. D., Belardinelli, L., & Antzelevitch, C. (2003) · Circulation · doi:10.1161/01.cir.0000085066.05180.40 · Cited by 121
Effect of renzapride on transit in constipation-predominant irritable bowel syndrome
Camilleri, M., McKinzie, S., Fox, J., Foxx–Orenstein, A. E., Burton, D. D., Thomforde, G. M., Baxter, K. L., & Zinsmeister, A. R. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00391-x · Cited by 118
Self-citationTreatment of Chronic Constipation: Current Pharmacologic Approaches and Future Directions
Tack, J. F., & Müller-Lissner, S. A. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.12.006 · Cited by 113
Self-citationDose finding study of mosapride in functional dyspepsia: a placebo‐controlled, randomized study
Hallerbäck, B., Bommelaer, G., Bredberg, E., Campbell, M., Hellblom, M., Lauritsen, K., WIENBECK, M., & Holmgren, L. ‐. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01236.x · Cited by 112
Kilbinger, H. J., & Wolf, D. (1992) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00168686 · Cited by 110
Tachycardia during cisapride treatment.
Olsson, S., & Edwards, I. R. (1992) · BMJ · doi:10.1136/bmj.305.6856.748-a · Cited by 109
5-HT4Receptor Ligands: Applications and New Prospects
Langlois, M., & Fischmeister, R. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020099f · Cited by 109
Mine, Y., Yoshikawa, T., Oku, S., et al. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37150-2 · Cited by 108
Treatment of chronic constipation with cisapride and placebo.
Müller-Lissner, S. A. (1987) · Gut · doi:10.1136/gut.28.8.1033 · Cited by 106
Self-citationFeldman, M. L., & Smith, H. J. (1987) · Gastroenterology · doi:10.1016/0016-5085(87)90854-7 · Cited by 106
Medhurst, A. D., Lezoualc’h, F., Fischmeister, R., Middlemiss, D. N., & Sanger, G. J. (2001) · Molecular Brain Research · doi:10.1016/s0169-328x(01)00095-x · Cited by 105
Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers
Emmanuel, A., Kamm, M., Roy, A., & Antonelli, K. (1998) · Gut · doi:10.1136/gut.42.4.511 · Cited by 105
Matsumoto, M., Togashi, H., Mori, K., Ueno, K.-I., Ohashi, S., Kojima, T., & Yoshioka, M. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38802-0 · Cited by 104
Sloots, C., Poen, A., Kerstens, R., Stevens, M., Pauw, M. D., van Oene, J. V., Meuwissen, S. G. M., & Felt-Bersma, R. (2002) · Alimentary Pharmacology and Therapeutics · doi:10.1046/j.1365-2036.2002.01210.x · Cited by 103
Ruth, Ruth, Hamelin, et al. (1998) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1998.00268.x · Cited by 102
Yan, Z. (2002) · Molecular Neurobiology · doi:10.1385/mn:26:2-3:203 · Cited by 100
Fraser, R. J., Horowitz, M., Maddox, A. F., & Dent, J. (1994) · Gut · doi:10.1136/gut.35.2.172 · Cited by 99
Pharmacodynamic effects of a novel prokinetic 5‐HT4 receptor agonist, ATI‐7505, in humans
Camilleri, M., Vázquez-Roque, M., Burton, D., Ford, T. J., Mckinzie, S., Zinsmeister, A., & Druzgala, P. (2007) · Neurogastroenterology and Motility · doi:10.1111/j.1365-2982.2006.00865.x · Cited by 98
Self-citationMushiroda, T., Douya, R., Takahara, E., & Nagata, O. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12055-x · Cited by 98
Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs
Briejer, M. R., Prins, N. H., & Schuurkes, J. A. J. (2001) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2001.00280.x · Cited by 94
Self-citationEffect of tegaserod on gut transit in male and female subjects
Degen, L. P., Petrig, C., Studer, D., Schroller, S., & Beglinger, C. (2005) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2005.00715.x · Cited by 89
Stacher, G., Bergmann, H., Wiesnagrotzki, S., Kiss, A., Schneider, C., Mittelbach, G., Gaupmann, G., & Höbart, J. (1987) · Gastroenterology · doi:10.1016/0016-5085(87)90976-0 · Cited by 88
The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada
Walker, A. M., Szneke, P., Weatherby, L. B., DICKER, L. W., Lanza, L. L., Loughlin, J. E., Yee, C. L., & Dreyer, N. A. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00241-7 · Cited by 88
Cucchiara, S., Staiano, A., Boccieri, A., et al. (1990) · Gut · doi:10.1136/gut.31.1.21 · Cited by 86
Yoshida, N., Takami, I. T. O., Karasawa, T., et al. (1991) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24782-6 · Cited by 82
Buchheit, K., Gamse, R., Giger, R., et al. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00013a010 · Cited by 81
Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility
Abell, T., Camilleri, M., Dimagno, E., Hench, V. S., Zinsmeister, A., & Malagelada, J. (1991) · Digestive Diseases and Sciences · doi:10.1007/bf01297028 · Cited by 81
Self-citationLong‐term safety of tegaserod in patients with constipation‐predominant irritable bowel syndrome
Tougas, G. H., Snape, W. J., Otten, M. H., Earnest, D. L., Langaker, K. E., Pruitt, R. E., Pecher, E., Nault, B., & Rojavin, M. A. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01347.x · Cited by 78
Brattelid, T., Qvigstad, E., Lynham, J. A., Molenaar, P., Aass, H., Geiran, O. R., Skomedal, T., Osnes, J. B., Levy, F. O., & Kaumann, A. (2004) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-004-0963-0 · Cited by 77
Poen, Felt-Bersma, Dongen, V., & Meuwissen (1999) · Alimentary Pharmacology and Therapeutics · doi:10.1046/j.1365-2036.1999.00629.x · Cited by 77
Cisapride restores the decreased lower oesophageal sphincter pressure in reflux patients.
Ceccatelli, P., Janssens, J., Vantrappen, G. R., et al. (1988) · Gut · doi:10.1136/gut.29.5.631 · Cited by 76
Development of drugs for gastrointestinal motor disorders: translating science to clinical need
Sanger, G. J., & Alpers, D. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2008.01084.x · Cited by 75
Ruth, M., Finizia, C. A., Cange, L., et al. (2003) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200310000-00009 · Cited by 73
Wardle, K. A., & Sanger, G. J. (1993) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1993.tb14006.x · Cited by 73
Asai, H., Udaka, F., Hirano, M., Minami, T., Oda, M., Kubori, T., Nishinaka, K., Kameyama, M., & Ueno, S. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2005.06.007 · Cited by 71
Morganroth, J., Rüegg, P. C., Dunger‐Baldauf, C., Appel‐Dingemanse, S., Bliesath, H., & Lefkowitz, M. P. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05986.x · Cited by 70
Markstein, R., Matsumoto, M., Kohler, C., Togashi, H., Yoshioka, M., & Hoyer, D. (1999) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/pl00005375 · Cited by 68
Heyland, D. K., Tougas, G. H., Cook, D. J., & Guyatt, G. H. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.154.6.8970354 · Cited by 67
Promotility Medications – Now and in the Future
Karamanolis, G., & Tack, J. F. (2006) · Digestive Diseases · doi:10.1159/000092883 · Cited by 67
Self-citationSmout, A. J. P. M., Bogaard, J. W., Grade, A., et al. (1985) · Gut · doi:10.1136/gut.26.3.246 · Cited by 67
Metoclopramide-Induced Parkinsonism
Indo, T. (1982) · Archives of Neurology · doi:10.1001/archneur.1982.00510200036006 · Cited by 66
Prins, N. H., Haselen, J. F. W. R. V., Lefebvre, R. A., et al. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702665 · Cited by 66
Effect of mosapride on gastrointestinal transit time and diagnostic yield of capsule endoscopy
Wei, W., Ge, Z., Lü, H., Gao, Y., Hu, Y., & Xiao, S. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05064.x · Cited by 66
Buchheit, K., Gamse, R., Giger, R., et al. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00013a009 · Cited by 64
Tegaserod‐Induced Myocardial Infarction: Case Report and Hypothesis
Busti, A. J., Murillo, J. R., & Cryer, B. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.5.526.33351 · Cited by 64
Smith, J. A. M., Beattie, D. T., Marquess, D. G., Shaw, J. P., Vickery, R. G., & Humphrey, P. P. A. (2008) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-008-0282-y · Cited by 62
Cisapride for the treatment of constipation in children: A double-blind study
Nurko, S., García-Aranda, J. A., Worona, L. B., et al. (2000) · The Journal of Pediatrics · doi:10.1016/s0022-3476(00)90046-5 · Cited by 61
The effect of oral cisapride on colonic transit
Krevsky, B., Malmud, L., Maurer, A. H., Somers, M., Siegel, J. A., & Fisher, R. S. (1987) · Alimentary Pharmacology and Therapeutics · doi:10.1111/j.1365-2036.1987.tb00629.x · Cited by 59
Cisapride in children with chronic intestinal pseudoobstruction
Lorenzo, C. D., Reddy, S. N., Villanueva‐Meyer, J., et al. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90393-y · Cited by 59
Coprescribing and Codispensing of Cisapride and Contraindicated Drugs
Jones, J. K. (2001) · JAMA · doi:10.1001/jama.286.13.1607 · Cited by 58
Effect of cisapride, a new prokinetic agent, on esophageal motor function
Gilbert, R. J., Dodds, W. J., Kahrilas, P. J., et al. (1987) · Digestive Diseases and Sciences · doi:10.1007/bf01296657 · Cited by 58
5‐HT4 receptors located on cholinergic nerves in human colon circular muscle
Leclere, P. G., Prins, N. H., Schuurkes, J. A. J., & Lefebvre, R. A. (2005) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2005.00621.x · Cited by 58
Self-citationInfluence of grapefruit juice on cisapride pharmacokinetics
Gross, A. S., Goh, Y. I., Addison, R. S., & Shenfield, G. M. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70133-5 · Cited by 57
Inauen, W., Emde, C., Weber, B., et al. (1993) · Gut · doi:10.1136/gut.34.8.1025 · Cited by 57
Cisapride accelerates colonic transit in constipated patients with colonic inertia.
Krevsky, B., Maurer, A. H., Ls, M., et al. (1989) · PubMed · Cited by 57
In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions.
Vickers, A. E. M., Zollinger, M., Dannecker, R., Tynes, R. E., Heitz, F., & Fischer, V. (2001) · PubMed · Cited by 55
5‐HT4 Receptors: Cloning and Expression of New Splice Variants
Claeysen, S., Faye, P., Sebben, M., Taviaux, S. A., Bockaert, J., & Dumuis, A. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb10172.x · Cited by 54
Tack, J. F., Middleton, S. J., HORNE, M. C., Piessevaux, H. H., Bloor, J., Meyers, N. L., & PALMER, R. M. J. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02940.x · Cited by 52
Self-citationAS-4370, a novel gastrokinetic agent free of dopamine D2 receptor antagonist properties.
Yoshida, N., Omoya, H., Oka, M., et al. (1990) · PubMed · Cited by 52
Effect of cisapride on delayed gastric emptying in gastro-oesophageal reflux disease.
Maddern, G. J., Jamieson, G. G., Myers, J. C., et al. (1991) · Gut · doi:10.1136/gut.32.5.470 · Cited by 51
The effect of cisapride on segmental colonic transit time in patients with spinal cord injury.
Geders, J. M., Gaing, A., Bauman, W. A., et al. (1995) · PubMed · Cited by 49
Evidence of impaired cisapride metabolism in neonates
Tréluyer, J., Rey, E., Sonnier, M., et al. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01470.x · Cited by 49
Cisapride reduces neonatal postoperative ileus: randomised placebo controlled trial
Lander, A., Redkar, R. G., Nicholls, G., et al. (1997) · Archives of Disease in Childhood Fetal & Neonatal · doi:10.1136/fn.77.2.f119 · Cited by 49
Chen, J. D. Z., Ke, M. Y., Lin, X., Wang, Z., & Zhang, M. (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00801.x · Cited by 49
Presynaptic modulation of cholinergic neurotransmission in the human proximal stomach
Leclere, P. G., & Lefebvre, R. A. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704471 · Cited by 49
Beattie, D. T., Armstrong, S. R., Shaw, J. P., Marquess, D. G., Sandlund, C., Smith, J. A. M., Taylor, J. A., & Humphrey, P. P. A. (2008) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-008-0281-z · Cited by 48
Borovicka, J., Lehmann, R., Kunz, P. L., et al. (1999) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01392.x · Cited by 47
Effect of cisapride on postprandial gastro-oesophageal reflux.
Holloway, R. H., Downton, J., Mitchell, B., et al. (1989) · Gut · doi:10.1136/gut.30.9.1187 · Cited by 47
Sun, H., & Scott, D. O. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200117z · Cited by 46
Prins, N. H., Shankley, N. P., Welsh, N. J., et al. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703254 · Cited by 45
Effects of cisapride on distal esophageal motility in humans
Corazziari, E. S., Bontempo, I., & Anzini, F. (1989) · Digestive Diseases and Sciences · doi:10.1007/bf01537117 · Cited by 44
Endo, J., Nomura, M., Morishita, S., Uemura, N., Inoue, S., Kishi, S., Kawaguchi, R., Iga, A., Ito, S., & Nakaya, Y. (2002) · Journal of Gastroenterology · doi:10.1007/s005350200150 · Cited by 44
Yoshida, N., Omoya, H., Kato, S., et al. (1993) · PubMed · Cited by 44
Stacher, G., Schernthaner, G., Francesconi, M., Kopp, H.-P., Bergmann, H., Stacher-Janotta, G., & Weber, U. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.7.5859 · Cited by 43
Randomised controlled trial of cisapride in preterm infants
McClure, R., Kristensen, J. H., & Grauaug, A. A. (1999) · Archives of Disease in Childhood Fetal & Neonatal · doi:10.1136/fn.80.3.f174 · Cited by 43
Appel-Dingemanse, S., Lemarechal, M.-O., Kumle, A., Hubert, M., & Legangneux, E. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00936.x · Cited by 42
GEORGE, A. M., Meyers, N. L., & Hickling, R. I. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03649.x · Cited by 42
Kilbinger, H. J., Gebauer, A., Haas, J., et al. (1995) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00233241 · Cited by 42
Toga, T., Kohmura, Y., & Kawatsu, R. (2007) · Journal of Pharmacological Sciences · doi:10.1254/jphs.sc0070243 · Cited by 41
Effects of cisapride on jejunal motor activity in fasting healthy humans
Stacher, G., Steinringer, H., Schneider, C., et al. (1986) · Gastroenterology · doi:10.1016/0016-5085(86)90387-2 · Cited by 40
Prokinetic effect of AS-4370 on gastric emptying in healthy adults
Kanaizumi, T., Nakano, H., Matsui, Y., Ishikawa, H., Shimizu, R., Park, S., & Kuriya, N. (1991) · European Journal of Clinical Pharmacology · doi:10.1007/bf00314963 · Cited by 40
Maeyer, J. H. D., Prins, N. H., Schuurkes, J. A. J., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.101329 · Cited by 40
Self-citationKawagishi, T., Nishizawa, Y., Okuno, Y., Sekiya, K., & Morii, H. (1993) · PubMed · Cited by 40
Harish, K., Hazeena, K., Thomas, V., Kumar, S., Jose, T., & Narayanan, P. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04543.x · Cited by 38
Richards, R., Valenzuela, G., Davenport, K., Fisher, K. L., & McCallum, R. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01295905 · Cited by 37
Longterm oral cisapride improves interdigestive antroduodenal motility in dyspeptic patients.
Testoni, P. A., Bagnolo, F., Fanti, L., Passaretti, S. M., & Tittobello, A. (1990) · Gut · doi:10.1136/gut.31.3.286 · Cited by 37
Anderson, J. L., May, H. T., Bair, T. L., Muhlestein, J. B., Horne, B. D., & Carlquist, J. F. (2009) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248409340158 · Cited by 37
QT prolongation and torsades de pointes associated with concurrent use of cisapride and erythromycin
Kyrmizakis, D. E., Chimona, T. S., KANOUPAKIS, E. M., et al. (2002) · American Journal of Otolaryngology · doi:10.1053/ajot.2002.124543 · Cited by 36
Ohki, R., Takahashi, M., Mizuno, O., et al. (2001) · Pacing and Clinical Electrophysiology · doi:10.1046/j.1460-9592.2001.00119.x · Cited by 35
The Effect of Mosapride on Esophageal Motility and Bolus Transit in Asymptomatic Volunteers
Cho, Y. K., Choi, M., Han, H. W., et al. (2006) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000210103.82241.97 · Cited by 35
Levy, J. F., Hayes, C., Kern, J., et al. (2001) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/00005176-200104000-00013 · Cited by 35
The effects of renzapride, a novel prokinetic agent, in diabetic gastroparesis
Mackie, A. D. R., Ferrington, C., COWAN, S., et al. (1991) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1991.tb00014.x · Cited by 34
Vaezi, M. F., Sears, R. J., & Richter, J. E. (1996) · Digestive Diseases and Sciences · doi:10.1007/bf02213132 · Cited by 34
Wager, E., Tooley, P., Pearce, G. L., et al. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050255 · Cited by 34
Dalby‐Payne, J., Morris, A., & Craig, J. C. (2003) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2003.02948.x · Cited by 34
AS-4370, a novel gastrokinetic agent free of D_2 receptor antagonist properties
Yoshida, N. (1989) · Medical Entomology and Zoology · Cited by 34
Besherdas, Leahy, Mason, et al. (1998) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1998.00369.x · Cited by 33
SAKASHITA, M., Yamaguchi, T., Miyazaki, H., et al. (1993) · PubMed · Cited by 32
Pehlivanov, N., Sarosiek, I., Whitman, R. A., et al. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01225.x · Cited by 32
Roberts, J. P., Benson, M. J., Rogers, J. E., et al. (1995) · Diseases of the Colon & Rectum · doi:10.1007/bf02052441 · Cited by 30
Syncopal Episodes Associated with Cisapride and Concurrent Drugs
Gray, V. S. (1998) · Annals of Pharmacotherapy · doi:10.1345/aph.17288 · Cited by 30
Safety, Tolerability, and Efficacy of Tegaserod over 13 Months in Patients with Chronic Constipation
Müller-Lissner, S. A., Kamm, M. A., Musoğlu, A., Earnest, D. L., Dunger‐Baldauf, C., & Shetzline, M. A. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00789.x · Cited by 29
Self-citationHatlebakk, J. G., Johnsson, F., VILIEN, M., et al. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709002988 · Cited by 29
Nagakura, Y., Akuzawa, S., Miyata, K., et al. (1999) · Pharmacological Research · doi:10.1006/phrs.1998.0454 · Cited by 29
Effect of Cisapride on the Gastro-Oesophageal Function in Normal Human Subjects
Wallin, L., Kruse-Andersen, S., Madsen, T., et al. (2009) · Digestion · doi:10.1159/000199494 · Cited by 28
Drug Interaction Between Mosapride and Erythromycin Without Electrocardiographic Changes.
Katoh, T., Saitoh, H., Ohno, N., Tateno, M., Nakamura, T., Dendo, I., Kobayashi, S., & Nagasawa, K. (2003) · Japanese Heart Journal · doi:10.1536/jhj.44.225 · Cited by 28
Chan, K. Y., VRIES, R. D., Leijten, F. P. J., et al. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.07.010 · Cited by 28
Stacher, G., Gaupmann, G., Mittelbach, G., et al. (1987) · Digestive Diseases and Sciences · doi:10.1007/bf01296370 · Cited by 28
Cisapride stimulates antral motility and decreases biliary reflux in patients with severe dyspepsia
Rezende-Filho, J., Lorenzo, C. D., Dooley, C. P., et al. (1989) · Digestive Diseases and Sciences · doi:10.1007/bf01536374 · Cited by 28
Finizia, C. A., Lundell, L. R., Cange, L., et al. (2002) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200201000-00003 · Cited by 28
Quigley, E. M. M., Wald, A. M., Fidelholtz, J., Boivin, M., Pecher, E., & Earnest, D. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.02.017 · Cited by 28
Self-citationCisapride stimulates propulsive motility patterns in human jejunum
Coremans, G., Janssens, J., Vantrappen, G., et al. (1988) · Digestive Diseases and Sciences · doi:10.1007/bf01535939 · Cited by 27
Jost, W. H., & Schimrigk, К. (1994) · PubMed · Cited by 27
Effect of cisapride on human fasting gallbladder volume: A real-time ultrasonographic study
Marzio, L., DiGiammarco, A. M., Capone, F., et al. (1986) · European Journal of Clinical Pharmacology · doi:10.1007/bf00635906 · Cited by 26
Itskowitz, M. S. (2004) · New England Journal of Medicine · doi:10.1056/nejm200409233511323 · Cited by 26
Martí-Massó, J. F., Carrera, N., Urtasun, M., et al. (1993) · Movement Disorders · doi:10.1002/mds.870080127 · Cited by 26
Selective desensitization of the 5‐HT4receptor‐mediated response in pig atrium but not in stomach
Maeyer, J. H. D., Schuurkes, J. A. J., & Lefebvre, R. A. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00007.x · Cited by 25
Self-citationPalme, M., Milner, P. G., Ellis, D. J., et al. (2010) · Gastroenterology · doi:10.1016/s0016-5085(10)60590-2 · Cited by 24
Stacher, G., Granser, G. V., Bergmann, H., et al. (1991) · Digestive Diseases and Sciences · doi:10.1007/bf01307519 · Cited by 24
Stacher, G. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.7.2357 · Cited by 23
Ray, A. M., Kelsell, R. E., Houp, J. A., et al. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.11.056 · Cited by 22
Ren, J., Zhou, X., & Galligan, J. J. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00078.2008 · Cited by 22
Self-citationSerotonergic signalling in the stomach and duodenum of patients with gastroparesis
van Lelyveld, N., ter Linde, J., Schipper, M., & Samsom, M. (2008) · Neurogastroenterology and Motility · doi:10.1111/j.1365-2982.2007.01068.x · Cited by 21
Tegaserod‐Associated Ischemic Colitis
DiBaise, J. K. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.25.4.620.61032 · Cited by 21
Goldberg, M. R., Li, Y.-P., Pitzer, K., et al. (2008) · Gastroenterology · doi:10.1016/s0016-5085(08)62543-3 · Cited by 21
Hancox, J. C., & James, A. F. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.047563 · Cited by 21
Schoenfeld, P. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.01864.x · Cited by 20
Noor, N. (1998) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365529850171873 · Cited by 20
Tegaserod and Ischemic Colitis
Brinker, A. D., Mackey, A. C., & Prizont, R. (2004) · New England Journal of Medicine · doi:10.1056/nejm200409233511324 · Cited by 20
Thumshirn, M. B., Fruehauf, H., STUTZ, B., et al. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03521.x · Cited by 19
Lazzaroni, M., Sangaletti, O., & Porro, B. (2009) · Digestion · doi:10.1159/000199476 · Cited by 19
The Cardiovascular Safety Profile of Renzapride, a Novel Treatment for Irritable Bowel Syndrome
Meyers, N. L., & Hickling, R. (2007) · Journal of International Medical Research · doi:10.1177/147323000703500613 · Cited by 19
Effects of oral cisapride on small bowel motility in irritable bowel syndrome
EVANS, P. R., Bak, Y., & Kellow, J. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.00240.x · Cited by 19
Pharmacology and Metabolism of Renzapride
Meyers, N. L., & Hickling, R. I. (2008) · Drugs in R&D · doi:10.2165/00126839-200809010-00004 · Cited by 18
Yoshida, N., & Takami, I. T. O. (1994) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.1994.tb00184.x · Cited by 18
Paterson, W. G., Wang, H., & Beck, I. T. (1997) · PubMed · Cited by 18
Cools, F., Benatar, A. A., Bruneel, E., et al. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0582-6 · Cited by 16
Spiller, R. E., Meyers, N. L., & Hickling, R. I. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0295-x · Cited by 16
Maeyer, J. H. D., Aerssens, J., Verhasselt, P., et al. (2008) · Physiological Genomics · doi:10.1152/physiolgenomics.00038.2008 · Cited by 16
Effects of cisapride on gastric emptying of oil and aqueous meal components, hunger, and fullness.
Jones, K. L., Horowitz, M., Carney, B. I., et al. (1996) · Gut · doi:10.1136/gut.38.3.310 · Cited by 16
Bowersox, S. S., Lightning, L. K., Rao, S. S. C., et al. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.037564 · Cited by 16
Fried, M., Beglinger, C., Bobalj, N. G., Minor, N., Coello, N., & Michetti, P. (2005) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200504000-00005 · Cited by 15
Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome
Scarpellini, E., & Tack, J. F. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.11.1663 · Cited by 15
Self-citationThe 5-HT2B antagonist and 5-HT4 agonist activities of tegaserod in the anaesthetized rat
MCCULLOUGH, J., Armstrong, S. L., Hegde, S. S., & BEATTIE, D. (2006) · Pharmacological Research · doi:10.1016/j.phrs.2006.01.003 · Cited by 15
Sabbatini, F., Minieri, M., Manzi, G., et al. (1991) · PubMed · Cited by 15
Orr, W. C., Chen, C. ‐., & Sloan, S. (2001) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2001.01080.x · Cited by 14
Should Cisapride Be Avoided in Patients with Diabetic Gastroparesis?
Evans, A. J., & Krentz, A. J. (1999) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(99)00058-6 · Cited by 14
SAKASHITA, M., Mizuki, Y., Yamaguchi, T., et al. (1993) · PubMed · Cited by 14
Salivary function in patients with reflux esophagitis: effect of cisapride.
Chen, S. D., Kao, C. H., Cs, C., et al. (1998) · PubMed · Cited by 13
Boyce, M. J., Kerstens, R., Beyens, G., Ausma, J., & Vandeplassche, L. M. (2009) · Gastroenterology · doi:10.1016/s0016-5085(09)62460-4 · Cited by 13
Effect of AS-4370 on gastric motility in patients with diabetic autonomic neuropathy.
Yamada, M. G., Hongo, M., OKUNO, Y., et al. (1992) · Journal of Smooth Muscle Research · doi:10.1540/jsmr.28.153 · Cited by 13
Effect of Clebopride, Antidopaminergic Gastrointestinal Prokinetics, on Cardiac Repolarization
Kim, K., Shin, W.-H., Park, S., et al. (2007) · International Journal of Toxicology · doi:10.1080/10915810601117992 · Cited by 12
QTc Interval in Infants Receiving Cisapride
Chhina, S., Peverini, R. L., Deming, D. D., et al. (2002) · Journal of Perinatology · doi:10.1038/sj.jp.7210613 · Cited by 12
Smythe, A., Bird, N. C., Troy, G., et al. (2003) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200303000-00014 · Cited by 11
Pharmacokinetic profile of cisapride 20 mg after once- and twice-daily dosing
Zhou, H., Herron, J. M., Clyde, C., et al. (1998) · Clinical Therapeutics · doi:10.1016/s0149-2918(98)80092-1 · Cited by 11
Manes, G., Domínguez‐Muñoz, J. E., Leodolter, A., et al. (2001) · Digestive and Liver Disease · doi:10.1016/s1590-8658(01)80012-8 · Cited by 11
Wooltorton, E. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1040882 · Cited by 11
Pouderoux, P., & Kahrilas, P. J. (1995) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1995.tb00436.x · Cited by 10
Research works printed but not linked: 15
- Novartis. Press release: Novartis suspends US marketing and sales of Zelnorm in response to request from FDA. Available at:http://hugin.info/134323/R/1116336/204121.pdf. Accessed December 14 2010.
- Dennis D, 2004, ATI‐7505 is a novel, selective 5HT(4) receptor agonist that causes gastrointestinal prokinetic activity in dogs, Gastroenterology, 126, A641
- Singh G, 2004, Patients with irritable bowel syndrome have a high risk of developing colon ischemia [abstract], Gut, 53, A66
- Joelsson B, 2004, Tegaserod and ischemic colitis, New Engl J Med, 351, 1363
- Alizyme. Press release: Results from Renzapride. April 2008. Available at:http://www.alizyme.com/alizyme/media/press/show.jsp?ref=128. Accessed December 14 2010.
- Corinaldesi R, 1985, Effects of chronic oral administration of clebopride and metoclopramide on gastric emptying of solids in patients with functional dyspepsia, Curr Ther Res, 38, 790
- Martinez‐Martin P, 1993, Transient dyskinesia induced by clebopride, Mov Disord, 8, 125
- Horri S, 2000, Clinical study on safety of mosapride in combination therapy with psychiatric drugs, Rinsho Iyaku, 16, 153
- Briejer MR, 1997, In vitro pharmacology of the novel enterokinetic R093877, Gastroenterology, 112, A705
- Dennis D, 2004, ATI‐7505 is a novel, selective 5HT(4) receptor agonist that causes gastrointestinal prokinetic activity in dogs, Gastroenterology, 126, A641
- AchtertG BorchersF FinnerE HausleiterHJ.Metabolism of clebopride in animals and man. In: Poster presented at the 12th European Workshop on Drug Metabolism; 1990;Basel Switzerland;1990.
- Vantrappen G, 1985, The effect of clebopride on lower esophageal sphincter pressure in normal subjects, Curr Ther Res, 37, 284
- 10.1016/0016-5085(89)90893-7 · DOI
- 10.1111/j.1365-2982.2009.01378.x · DOI
- Elorza JM, 1982, Double‐blind parallel comparison of the gastrokinetic effects of clebopride, domperidone and placebo in human volunteers with gastric stasis induced by glucagon, Curr Ther Res, 31, S58
Cited by
Sorted by citations
Serotonin signalling in the gut: functions, dysfunctions and therapeutic targets
Mawe, G. M., & Hoffman, J. M. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.105 · Cited by 1,165
Gastroparesis: a turning point in understanding and treatment
Grover, M., Farrugia, G., & Stanghellini, V. (2019) · Gut · doi:10.1136/gutjnl-2019-318712 · Cited by 256
Self-citationPrucalopride in Gastroparesis: A Randomized Placebo-Controlled Crossover Study
Carbone, F., Van den Houte, K., Clevers, E., Andrews, C. N., Papathanasopoulos, A., Holvoet, L., Van Oudenhove, L., Caenepeel, P., Arts, J., Vanuytsel, T., et al. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000304 · Cited by 206
Self-citationChang, L., Sultan, S., Lembo, A., Verne, G. N., Smalley, W., & Heidelbaugh, J. J. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.04.016 · Cited by 163
Self-citationSerotonin as a link between the gut-brain-microbiome axis in autism spectrum disorders
Israelyan, N., & Margolis, K. G. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.020 · Cited by 122
Metadata
- Authors
- Tack, J., Camilleri, M., Chang, L., Chey, W. D., Galligan, J. J., Lacy, B. E., Müller‐Lissner, S., Quigley, E. M. M., Schuurkes, J., De Maeyer, J. H., & Stanghellini, V.
- Affiliations
- KU Leuven (BE)
- Mayo Clinic (US)
- University of California, Los Angeles (US)
- Michigan Medicine (US)
- Michigan State University (US)
- Dartmouth–Hitchcock Medical Center (US)
- Department of Internal Medicine, Park‐Klinik Weissensee Berlin Germany
- University College Cork (IE)
- Shire‐Movetis NV Turnhout Belgium
- University of Bologna (IT)
- Corresponding author
- Tack, J.
- ORCID
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2012-02-22
- Volume
- 35
- Issue
- 7
- Pages
- 745-767
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- PMC
- PMC3491670
- OpenAlex
- W2075335843
- Cited by
- 286
- References
- 214
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 11 · 2023: 7 · 2022: 15 · 2021: 30 · 2020: 24 · 2019: 16 · 2018: 21 · 2017: 23 · 2016: 30 · 2015: 20 · 2014: 29 · 2013: 18 · 2012: 11
- FWCI
- 3.70
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Alimentary Pharmacology & Therapeutics (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- Falk Foundation
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Ikaria
- Danone
- Ironwood Pharmaceuticals, Incorporated
- Novo Nordisk
- Astellas Pharma
- Ipsen
- Norgine
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Gastroenterology › Gastroesophageal reflux and treatments
- Keywords
- 5-HT4 receptor agonist, cardiovascular safety, cisapride, tegaserod, prucalopride, clebopride, mosapride, renzapride, QT prolongation, myocardial ischemia, hERG, gastrointestinal motility disorders, drug selectivity, adverse drug reactions
- MeSH terms
- Cardiovascular Diseases, Gastrointestinal Agents, Gastrointestinal Diseases, Humans, Indoles, Randomized Controlled Trials as Topic, Cisapride, Serotonin 5-HT4 Receptor Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
